Holen Sie sich die Stockscreener-App
15.57
1.57%
0.24
Handel nachbörslich:
15.57
Schlusskurs vom Vortag:
$15.33
Offen:
$15.6
24-Stunden-Volumen:
1.40M
Relative Volume:
1.32
Marktkapitalisierung:
$949.53M
Einnahmen:
$13.73M
Nettoeinkommen (Verlust:
$-114.48M
KGV:
-8.4537
EPS:
-1.8418
Netto-Cashflow:
$-78.49M
1W Leistung:
-2.99%
1M Leistung:
+4.22%
6M Leistung:
+5.70%
1J Leistung:
-40.02%
1-Tages-Spanne:
$15.29
$15.95
1-Wochen-Bereich:
$15.24
$16.36
52-Wochen-Spanne:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
Firmenname
Janux Therapeutics Inc
Sektor
Branche
Telefon
(858) 751-4493
Adresse
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
15.57 | 934.89M | 13.73M | -114.48M | -78.49M | -1.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Herabstufung | Barclays | Overweight → Underweight |
| 2026-04-15 | Herabstufung | UBS | Buy → Neutral |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-10 | Eingeleitet | Stifel | Buy |
| 2025-09-10 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-07-11 | Eingeleitet | Raymond James | Outperform |
| 2024-12-03 | Bestätigt | BTIG Research | Buy |
| 2024-12-03 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-05-30 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-03-21 | Eingeleitet | BTIG Research | Buy |
| 2024-03-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Eingeleitet | Wedbush | Outperform |
| 2022-11-14 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
Janux Therapeutics Inc (JANX) Balance Sheet - TradingKey
JANX|Janux Therapeutics Inc|Price:15.680|Chg%:+0.350 - TradingKey
Janux Therapeutics Inc (JANX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
JANX|Janux Therapeutics Inc|Price:15.510|Chg%:+0.180 - TradingKey
Janux Therapeutics Inc (JANX) Income Statement - TradingKey
Janux Therapeutics Inc (JANX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits
Janux Therapeutics, Inc. (JANX) Stock Price, News, Quote & History - Yahoo! Finance Canada
3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership - Moomoo
Janux Therapeutics Inc (JANX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Janux Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Barrett Ronald W - Moomoo
Janux Therapeutics, Inc. (JANX) Stock Analysis: A Biotech Powerhouse with 131.70% Potential Upside - DirectorsTalk Interviews
Avoiding Lag: Real-Time Signals in (JANX) Movement - Stock Traders Daily
Janux Therapeutics (JANX) Gains Momentum: Biotech Stock Rises 2.65% as Buyers Test Key ResistanceIPO Entry Watch - dars.gov.et
Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains? - MSN
JANX News | JANUX THERAPEUTICS INC (NASDAQ:JANX) - ChartMill
Janux Therapeutics (NASDAQ: JANX) CEO exercises 7,000 options at $4.21, boosts holdings - Stock Titan
Is Janux Therapeutics’ (JANX) Russell Index Exit Quietly Rewriting Its Investor Base and Story? - Yahoo Finance
Janux Therapeutics (JANX) Is Up 13.6% After Removal From Multiple Russell Growth IndexesWhat's Changed - simplywall.st
Janux Therapeutics Q1 2026 Earnings: Loss Narrower Than Expected, Stock Rises 6%Dividend Cut Risk - dars.gov.et
Price to earnings forward of Janux Therapeutics, Inc. – NASDAQ:JANX - TradingView
Price to sales forward of Janux Therapeutics, Inc. – NASDAQ:JANX - TradingView
Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential? - Yahoo Finance
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 3000 Growth Benchmark - marketscreener.com
5 Most Promising Cancer Stocks According to Wall Street Analysts - Insider Monkey
Discipline and Rules-Based Execution in JANX Response - Stock Traders Daily
Janux Therapeutics (JANX) Gains 2.47% as Shares Hold Above Key Support LevelDiagonal Spread Trade - dars.gov.et
JANX Forecast — Price Target — Prediction for 2027 - TradingView
Janux Therapeutics, Inc. Actuals & Estimates (NASDAQ:JANX) - TradingView
Janux Therapeutics, Inc. Actuals & Estimates (BX:JANX) - TradingView
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Truist Financial Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $26 - Moomoo
Form 8K Janux Therapeutics Inc For: 23 June By Investing.com - Investing.com India
Janux Therapeutics announces departure of chief medical officer By Investing.com - Investing.com Australia
Janux Therapeutics Announces Departure of Chief Medical Officer - TipRanks
Janux Therapeutics announces departure of chief medical officer - Investing.com
CMO exits Janux Therapeutics (NASDAQ: JANX) as company starts search - Stock Titan
Janux Therapeutics (JANX) Gains Modestly Amid Biotech Sector CautionInstitutional Buy Signals - dars.gov.et
JANX Q1 2026 Earnings: EPS Surprise Beats Estimates Amid Clinical ProgressAnalyst Coverage Count - dars.gov.et
Janux Therapeutics Inc (JANX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Finanzdaten der Janux Therapeutics Inc-Aktie (JANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):